



#35 RECEIVED

Geiga

FEB 26 2003

TECH CENTER 1600/2900

PETITION AND FEE FOR EXTENSION OF TIME UNDER 37 CFR §1.136(a)

Examining Group 1644

Patent Application

Docket No. SPO-103

Serial No. 09/142,524

RECEIVED

FEB 25 2003

TC 1700

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents

Washington, D.C. 20231 on February 12, 2003

Frank C Eisenschenk

Frank C. Eisenschenk, Ph.D., Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Marianne DiBrino, Ph.D.

Art Unit : 1644

Applicants : Toshio Sone, Akinori Kume, Kazuo Dairiki, Akiko Iwama, Kohsuke Kino

Serial No. : 09/142,524

Filed : September 9, 1998

For : Peptide-Based Immunotherapeutic Agent for Treating Allergic Diseases

Assistant Commissioner for Patents

Washington, D.C. 20231

PETITION AND FEE FOR EXTENSION OF TIME
UNDER 37 CFR §1.136(a)

Sir:

Applicants request that the period for response be extended three months through and including February 13, 2003. An Amendment Under 37 CFR §1.111 accompanies this Petition. Please charge the fee of \$930.00 to Deposit Account No. 19-0065.

Any additional fees as required by 37 CFR §§1.16 or 1.17 should be charged to Deposit Account No. 19-0065. Two additional copies of this Petition are enclosed.

Respectfully submitted,

Frank C Eisenschenk

Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332


Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: 2421 N.W. 41st Street, Suite A-1
Gainesville, FL 32606-6669

FCE/sl

Attachment: Amendment Under 37 CFR §1.111



16448
OMB No. 0651-0011 (12/31/86)

AMENDMENT TRANSMITTAL LETTER				ATTORNEY'S DOCKET NO. SPO-103
SERIAL NO. 09/142,524	FILING DATE September 9, 1998	EXAMINER Marianne DiBrino, Ph.D.	GROUP ART UNIT 1644	
INVENTION Peptide-Based Immunotherapeutic Agent for Treating Allergic Diseases				

TO THE COMMISSIONER OF PATENTS AND TRADEMARKS:

Transmitted herewith is an amendment in the above-identified application.

- Small entity status of this application under 37 CFR 1.27 has been established by a verified statement previously submitted.
- A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed.
- No additional fee is required.
- The fee has been calculated as shown below:

	(1)	(2)	(3)	SMALL ENTITY	OTHER THAN A SMALL ENTITY
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA	
TOTAL	* 30	MINUS	** 24	6	
INDEP.	* 5	MINUS	*** 3	2	
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM				1	
				RATE \$ 9 \$42 \$140 Total addit. fee	RATE \$18 \$84 \$280 Total addit. fee
				ADDIT. FEE \$0.00 \$0.00 \$0.00 \$0.00	ADDIT. FEE \$108.00 \$168.00 \$280.00 \$388.00
				OR	OR

* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

** If the Highest No. Previously Paid For IN THIS SPACE is less than 20, enter "20."

*** If the Highest No. Previously Paid For IN THIS SPACE is less than 3, enter "3."

The Highest No. Previously Paid For (Total or Indep.) is the highest number found in the appropriate box in Col. 1.

- Please charge my Deposit Account No. 19-0065 in the amount of \$ 388.00.
- A check in the amount of \$ _____ to cover the filing fee is enclosed.
- The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 19-0065.
 - Any additional filing fees required under 37 CFR 1.16.
 - Any patent application processing fees under 37 CFR 1.17.

February 12, 2003
(date)

Leah C. Grenden
(signature)